Cargando…

Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry

INTRODUCTION: Atrial fibrillation and associated comorbidities pose a risk factor for mortality, morbidity and development of complications in patients admitted for COVID-19. OBJECTIVES: To describe the clinical, epidemiological, radiological and analytical characteristics of patients with AF admitt...

Descripción completa

Detalles Bibliográficos
Autores principales: Azaña Gómez, Javier, Pérez-Belmonte, Luis M., Rubio-Rivas, Manuel, Bascuñana, José, Quirós-López, Raúl, Taboada Martínez, María Luisa, Montero Hernandez, Esther, Roque-Rojas, Fernando, Méndez-Bailón, Manuel, Gómez-Huelgas, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier España, S.L.U. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579895/
https://www.ncbi.nlm.nih.gov/pubmed/36275872
http://dx.doi.org/10.1016/j.medcle.2022.01.020
_version_ 1784812280844648448
author Azaña Gómez, Javier
Pérez-Belmonte, Luis M.
Rubio-Rivas, Manuel
Bascuñana, José
Quirós-López, Raúl
Taboada Martínez, María Luisa
Montero Hernandez, Esther
Roque-Rojas, Fernando
Méndez-Bailón, Manuel
Gómez-Huelgas, Ricardo
author_facet Azaña Gómez, Javier
Pérez-Belmonte, Luis M.
Rubio-Rivas, Manuel
Bascuñana, José
Quirós-López, Raúl
Taboada Martínez, María Luisa
Montero Hernandez, Esther
Roque-Rojas, Fernando
Méndez-Bailón, Manuel
Gómez-Huelgas, Ricardo
author_sort Azaña Gómez, Javier
collection PubMed
description INTRODUCTION: Atrial fibrillation and associated comorbidities pose a risk factor for mortality, morbidity and development of complications in patients admitted for COVID-19. OBJECTIVES: To describe the clinical, epidemiological, radiological and analytical characteristics of patients with AF admitted for COVID-19 in Spain. Secondarily, we aim to identify those variables associated with mortality and poor prognosis of COVID-19 in patients with AF. METHODS: Retrospective, observational, multicenter, nationwide, retrospective study of patients hospitalized for COVID-19 from March 1 to October 1, 2020. Data were obtained from the SEMI-COVID-19 Registry of the Spanish Society of Internal Medicine (SEMI) in which 150 Spanish hospitals participate. RESULTS: Between March 1 and October 1, 2020, data from a total of 16,461 patients were entered into the SEMI-COVID-19 registry. 1,816 (11%) had a history of AF and the number of deaths among AF patients amounted to 738 (41%). Regarding clinical characteristics, deceased patients were admitted with a higher heart rate (88.38 vs 84.95; p > 0.01), with a higher percentage of respiratory failure (67.2% vs 20.1%; p < 0.01) and high tachypnea (58% vs 30%; p < 0.01). The comorbidities that presented statistically significant differences in the deceased group were: age, hypertension and diabetes with target organ involvement. There was also a higher prevalence of a history of cardiovascular disease in the deceased. On multivariate analysis, DOACs treatment had a protective role for mortality (OR:0,597) IC (0,402-0,888 ; p = 0.011). CONCLUSIONS: Previous treatment with DOACs and DOACs treatment during admission seem to have a protective role in patients with AF, although this fact should be verified in prospective studies.
format Online
Article
Text
id pubmed-9579895
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier España, S.L.U.
record_format MEDLINE/PubMed
spelling pubmed-95798952022-10-19 Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry Azaña Gómez, Javier Pérez-Belmonte, Luis M. Rubio-Rivas, Manuel Bascuñana, José Quirós-López, Raúl Taboada Martínez, María Luisa Montero Hernandez, Esther Roque-Rojas, Fernando Méndez-Bailón, Manuel Gómez-Huelgas, Ricardo Med Clin (Engl Ed) Original Article INTRODUCTION: Atrial fibrillation and associated comorbidities pose a risk factor for mortality, morbidity and development of complications in patients admitted for COVID-19. OBJECTIVES: To describe the clinical, epidemiological, radiological and analytical characteristics of patients with AF admitted for COVID-19 in Spain. Secondarily, we aim to identify those variables associated with mortality and poor prognosis of COVID-19 in patients with AF. METHODS: Retrospective, observational, multicenter, nationwide, retrospective study of patients hospitalized for COVID-19 from March 1 to October 1, 2020. Data were obtained from the SEMI-COVID-19 Registry of the Spanish Society of Internal Medicine (SEMI) in which 150 Spanish hospitals participate. RESULTS: Between March 1 and October 1, 2020, data from a total of 16,461 patients were entered into the SEMI-COVID-19 registry. 1,816 (11%) had a history of AF and the number of deaths among AF patients amounted to 738 (41%). Regarding clinical characteristics, deceased patients were admitted with a higher heart rate (88.38 vs 84.95; p > 0.01), with a higher percentage of respiratory failure (67.2% vs 20.1%; p < 0.01) and high tachypnea (58% vs 30%; p < 0.01). The comorbidities that presented statistically significant differences in the deceased group were: age, hypertension and diabetes with target organ involvement. There was also a higher prevalence of a history of cardiovascular disease in the deceased. On multivariate analysis, DOACs treatment had a protective role for mortality (OR:0,597) IC (0,402-0,888 ; p = 0.011). CONCLUSIONS: Previous treatment with DOACs and DOACs treatment during admission seem to have a protective role in patients with AF, although this fact should be verified in prospective studies. Published by Elsevier España, S.L.U. 2022-11-25 2022-10-13 /pmc/articles/PMC9579895/ /pubmed/36275872 http://dx.doi.org/10.1016/j.medcle.2022.01.020 Text en © 2022 Published by Elsevier España, S.L.U. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Azaña Gómez, Javier
Pérez-Belmonte, Luis M.
Rubio-Rivas, Manuel
Bascuñana, José
Quirós-López, Raúl
Taboada Martínez, María Luisa
Montero Hernandez, Esther
Roque-Rojas, Fernando
Méndez-Bailón, Manuel
Gómez-Huelgas, Ricardo
Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry
title Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry
title_full Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry
title_fullStr Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry
title_full_unstemmed Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry
title_short Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry
title_sort mortality risk factors in patients with sars-cov-2 infection and atrial fibrillation: data from the semi-covid-19 registry
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579895/
https://www.ncbi.nlm.nih.gov/pubmed/36275872
http://dx.doi.org/10.1016/j.medcle.2022.01.020
work_keys_str_mv AT azanagomezjavier mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry
AT perezbelmonteluism mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry
AT rubiorivasmanuel mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry
AT bascunanajose mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry
AT quiroslopezraul mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry
AT taboadamartinezmarialuisa mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry
AT monterohernandezesther mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry
AT roquerojasfernando mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry
AT mendezbailonmanuel mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry
AT gomezhuelgasricardo mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry
AT mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry